<DOC>
	<DOC>NCT00453349</DOC>
	<brief_summary>To assess the efficacy and safety of oral moxifloxacin compared to oral levofloxacin plus oral metronidazole in uncomplicated pelvic inflammatory disease (PID)</brief_summary>
	<brief_title>A Trial Comparing Moxifloxacin Versus Levofloxacin Plus Metronidazole In Uncomplicated Pelvic Inflammatory Disease</brief_title>
	<detailed_description />
	<mesh_term>Pelvic Inflammatory Disease</mesh_term>
	<mesh_term>Pelvic Infection</mesh_term>
	<mesh_term>Levofloxacin</mesh_term>
	<mesh_term>Ofloxacin</mesh_term>
	<mesh_term>Moxifloxacin</mesh_term>
	<mesh_term>Fluoroquinolones</mesh_term>
	<mesh_term>Metronidazole</mesh_term>
	<mesh_term>Norgestimate, ethinyl estradiol drug combination</mesh_term>
	<criteria>Diagnosis of uncomplicated PID based on the absence of pelvic or tuboovarian abscess at pelvic ultrasound and/or laparoscopic examination. Subjects with impaired liver and renal function; known hypersensitivity to study drugs, related compounds or any of the excipients.</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Uncomplicated pelvic inflammatory disease</keyword>
</DOC>